13 results about "Early onset" patented technology

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

Disclosed herein are methods, devices, and systems for the enhanced monitoring of visual function via telemedicine to detect early onset of changes and abnormalities associated with disease. The systems include a cloud environment or neural network communicating various tests and images to a client device in which a user / patient is properly positioned to view a display of the client device, receive stimuli, and provide patient input which is evaluated in terms of timing and substance to generate a contrast-sensitivity map of a visual function for the patient. Various ocular tests are described for implementation in a new home-based computer environment rather than using expensive and specific medical equipment in a doctor's office.

The present application relates to amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof. Specifically, the present application relates to double stranded ribonucleic acid (dsRNAi) agents and compositions that target the APP gene, as well as methods of using the dsRNAi agents and compositions to inhibit expression of the APP gene and methods of treating individuals having APP-related diseases or conditions, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer's disease (EOFAD or eFAD).

Disclosed are methods, kits, and models for identifying early onset sepsis (EOS) in a subject based on the levels of at least three proteins selected from CRP, EBP, SAA1, LRG1, and SERPINA3 or RNAs encoding said proteins.

The invention provides a monoclonal antibody designed for diagnosis and early detection of prostate cancer, and particularly relates to a specific monoclonal antibody developed to target soluble ADAM9 variants (sADAM9v2) secreted near prostate cancer.

The present application relates to the technical field of pregnancy rate prediction, and particularly relates to a model establishment method and system for predicting pregnancy rate of early-onset ovarian dysfunction, which obtains clinical data of a patient, identifies four types of prediction key points, including basic physiological characteristics, ovarian reserve function, treatment intervention and pregnancy outcome correlation. When the total amount of key points exceeds a first threshold value, a dimensionality reduction improved feedforward neural network is constructed, and basic physiological characteristics and treatment intervention data are used as inputs to predict ovarian function and pregnancy outcome. When the number of key points is small, a graph neural network is used, a directed graph structure is constructed based on clustering and hierarchical relationship of each key point, and node state is dynamically updated based on basic physiological characteristics, so as to realize classification prediction of ovarian function and pregnancy risk, improve prediction accuracy and model interpretability, and provide personalized and intelligent decision support for fertility evaluation of POI patients.

The present disclosure features useful methods to treat a SCN2A-related disorder caused by a gain-of-function SCN2A mutation using an SCN2A inhibitor. The present disclosure also features useful methods to treat a SCN2A-related disorder caused by a loss-of-function SCN2A mutation using an SCN2A enhancer. By monitoring the early onset seizure status of a subject, appropriate treatments can be administered more quickly without having to verify whether the subject has a gain-of-function or loss-of-function SCN2A mutation.

Methods and kits are disclosed to detect the early onset, determine the risk and / or severity, diagnose, and determine the progression or regression of radiotherapy-associated neuronal damage derived from samples of a subject by quantifying one or more biomarkers at concentrations indicative of the condition. The one or more biomarkers comprise neurofilament light chain (NfL).

Disclosed herein are methods, devices, and systems for the enhanced monitoring of visual function via telemedicine to detect early onset of changes and abnormalities associated with disease. The systems include a cloud environment or neural network communicating various tests and images to a client device in which a user / patient is properly positioned to view a display of the client device, receive stimuli, and provide patient input which is evaluated in terms of timing and substance to generate a contrast-sensitivity map of a visual function for the patient. Various ocular tests are described for implementation in a new home-based computer environment rather than using expensive and specific medical equipment in a doctor's office.

The present invention provides a monoclonal antibody designed for the diagnosis and early detection of prostate cancer, particularly in relation to a monoclonal antibody developed to target the specificity of soluble ADAM9 variants (sADAM9v2) secreted in the vicinity of prostate cancer.

Disclosed is an approach that may include generating and / or using a predictive machine learning classifier comprising one or more artificial neural networks. The classifier is configured to output a prediction related to developing preeclampsia (e.g., early onset preterm preeclampsia) during a current pregnancy of a patient based on health characteristics and one or more DNA metrics. The health characteristics and DNA metrics, such as total cell-free DNA (cfDNA) and fetal fraction (FF), may be obtained during a routine and non-invasive or minimally-invasive prenatal screening. The predictive machine learning classifier may be generated by applying deep learning techniques to data on subjects in a cohort. The data may comprise features corresponding to outcomes of prior pregnancies, health indicators, and one or more cfDNA measurements. First trimester risk assessment for preterm preeclampsia can identify patients most likely to benefit from preventative treatment protocols with a minimal or low level of intervention.